Latest Period
Q1 2026
Security Snapshot
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO) Institutional Ownership
CUSIP: 10806X102
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
455
Shares (Excl. Options)
194,114,219
Price
$74.26
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Symbol
- BBIO on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 194,114,219
- Total 13F value
- $14,417,533,009
- Portfolio coverage rank
- 0.01%
- Share change
- +5,565,492
- Value change
- +$397,787,161
- Number of holders
- 455
- Shares outstanding
- 196,655,058
- SEC-reported price per share
- $68.45
- Insider filing price
- $68.45
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BBIO - BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 10806X102.
- 455 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 428 to 455 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $14,404,279,010 to $14,417,533,009.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 455 institutions filings for Q1 2026.
Security key
10806X102
Latest holder period
Q1 2026
13F holders
455
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
BBIO full holder history
BridgeBio Pharma, Inc. SEC filings
BridgeBio Pharma, Inc. company facts
BridgeBio Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 10806X102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
BBIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| KKR Genetic Disorder L.P. | 7% | -31% | $476,864,517 | -$215,760,000 | 13,260,971 | -31% | KKR Genetic Disorder L.P. | 12 May 2025 |
| JANUS HENDERSON GROUP PLC | 6.8% | +18% | $977,092,024 | +$161,518,142 | 13,179,013 | +20% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| VIKING GLOBAL INVESTORS LP | 6.1% | -10% | $880,129,695 | -$87,989,901 | 11,842,434 | -9.1% | VIKING GLOBAL INVESTORS LP | 31 Mar 2026 |
| Farallon Capital Partners, L.P. | 5.2% | $674,408,855 | 10,226,063 | Dapice Joshua J. | 22 May 2026 | |||
| Kumar Neil | 4.6% | -16% | $689,354,243 | -$87,903,790 | 9,282,982 | -11% | NEIL KUMAR | 31 Mar 2026 |
As of 31 Mar 2026, 455 institutional investors reported holding 194,114,219 shares of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (the "Shares") (BBIO). This represents 99% of the company’s total 196,655,058 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
68%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | 14,207,757 | -2.3% | 0.02% | $1,055,068,019 |
| Kohlberg Kravis Roberts & Co. L.P. | 6.7% | 13,260,971 | 0% | 18% | $984,759,706 |
| JANUS HENDERSON GROUP PLC | 6.7% | 13,179,013 | +20% | 0.47% | $978,607,712 |
| VIKING GLOBAL INVESTORS LP | 6% | 11,842,434 | -18% | 2.5% | $879,419,149 |
| FARALLON CAPITAL MANAGEMENT LLC | 4.8% | 9,365,463 | +4.1% | 4.5% | $695,479,282 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1% | 8,080,573 | 0% | 0.03% | $600,063,351 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 7,759,495 | 0% | 0.01% | $576,220,099 |
| Aisling Capital Management LP | 2.6% | 5,089,611 | 0% | 79% | $377,954,513 |
| STATE STREET CORP | 2.5% | 4,934,320 | -0.58% | 0.01% | $366,422,603 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 4,918,030 | +11% | 0.02% | $371,928,018 |
| Invesco Ltd. | 2.3% | 4,592,814 | -4.9% | 0.05% | $341,062,368 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 3,801,655 | -0.71% | 0.03% | $282,312,000 |
| Frazier Life Sciences Management, L.P. | 1.8% | 3,448,139 | -2.7% | 6.6% | $256,058,802 |
| CITADEL ADVISORS LLC | 1.6% | 3,173,940 | +355% | 0.17% | $235,696,785 |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 3,120,631 | +60% | 0.19% | $231,738,058 |
| D. E. Shaw & Co., Inc. | 1.3% | 2,545,486 | +15% | 0.15% | $189,027,791 |
| Polar Capital Holdings Plc | 1.3% | 2,519,306 | +94% | 0.82% | $187,083,664 |
| WELLINGTON MANAGEMENT GROUP LLP | 1.3% | 2,483,953 | +5.8% | 0.03% | $184,458,350 |
| FRANKLIN RESOURCES INC | 1.2% | 2,438,925 | +13% | 0.04% | $181,114,553 |
| FMR LLC | 1.2% | 2,343,754 | -1.9% | 0.01% | $174,047,182 |
| UBS Group AG | 1% | 2,026,821 | +8.1% | 0.03% | $150,511,728 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1% | 1,977,080 | +0.09% | 0.13% | $146,817,961 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1% | 1,976,094 | +0.59% | 0.02% | $146,744,740 |
| ALLIANCEBERNSTEIN L.P. | 0.97% | 1,908,907 | -6.9% | 0.05% | $146,012,296 |
| GOLDMAN SACHS GROUP INC | 0.96% | 1,897,716 | +6.4% | 0.02% | $140,924,390 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
28
Latest
Q1 2026
Rows shown
1-25 of 28
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 194,114,219 | $14,417,533,009 | +$397,787,161 | $74.26 | 455 |
| 2025 Q4 | 188,214,100 | $14,404,279,010 | +$186,537,774 | $76.49 | 428 |
| 2025 Q3 | 184,963,434 | $9,606,937,258 | -$158,160,333 | $51.94 | 389 |
| 2025 Q2 | 188,818,044 | $8,154,464,813 | +$171,957,099 | $43.18 | 357 |
| 2025 Q1 | 185,173,982 | $6,405,659,483 | +$325,204,372 | $34.57 | 302 |
| 2024 Q4 | 176,645,317 | $4,847,193,349 | +$87,655,048 | $27.44 | 260 |
| 2024 Q3 | 172,596,886 | $4,393,814,683 | -$68,086,150 | $25.46 | 251 |
| 2024 Q2 | 174,953,530 | $4,431,556,073 | +$57,307,408 | $25.33 | 249 |
| 2024 Q1 | 171,539,419 | $5,303,582,949 | +$162,256,099 | $30.92 | 240 |
| 2023 Q4 | 165,715,337 | $6,690,573,516 | +$142,779,397 | $40.37 | 246 |
| 2023 Q3 | 161,102,840 | $4,243,730,776 | +$304,390,990 | $26.37 | 219 |
| 2023 Q2 | 149,815,028 | $2,576,329,186 | -$39,862,601 | $17.20 | 196 |
| 2023 Q1 | 152,372,388 | $2,526,139,807 | +$155,256,748 | $16.58 | 210 |
| 2022 Q4 | 144,623,389 | $1,101,997,850 | -$14,634,842 | $7.62 | 175 |
| 2022 Q3 | 145,248,661 | $1,443,911,522 | +$48,733,339 | $9.94 | 170 |
| 2022 Q2 | 140,449,294 | $1,275,283,327 | -$23,547,672 | $9.08 | 153 |
| 2022 Q1 | 143,303,557 | $1,454,787,082 | -$23,988,513 | $10.15 | 167 |
| 2021 Q4 | 141,976,495 | $2,367,117,577 | -$117,448,257 | $16.68 | 181 |
| 2021 Q3 | 140,028,398 | $6,563,888,337 | -$165,004,819 | $46.87 | 206 |
| 2021 Q2 | 142,676,491 | $8,697,122,835 | +$97,636,690 | $60.96 | 197 |
| 2021 Q1 | 141,085,070 | $8,688,930,801 | +$1,238,074,220 | $61.60 | 194 |
| 2020 Q4 | 121,079,579 | $8,609,553,572 | +$172,667,185 | $71.11 | 160 |
| 2020 Q3 | 117,841,767 | $4,393,419,330 | +$21,644,575 | $37.52 | 128 |
| 2020 Q2 | 117,300,177 | $3,824,660,106 | +$145,729,688 | $32.61 | 114 |
| 2020 Q1 | 112,894,365 | $3,273,779,385 | +$162,480,179 | $29.00 | 93 |